Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Multiple Myeloma 4Leukemia, Lymphocytic, Chronic, B-Cell 4Breast Neoplasms 3Triple Negative Breast Neoplasms 2Melanoma 2Lymphoma, Non-Hodgkin 2Leukemia, Myeloid, Acute 2rrCLL 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Neoplasms 1Lymphoma, Mantle-Cell 1Leukemia, Prolymphocytic 1Leukemia, B-Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms, Male 1Advanced Malignant Solid Neoplasm 1

Interventions

Interviews as Topic 3Educational Status 3veliparib 2adavosertib 2Specimen Handling 2Palliative Care 2Methods 2Early Intervention, Educational 2trametinib 1spartalizumab 1siltuximab 1pembrolizumab 1pamiparib 1dinaciclib 1cabozantinib 1Temozolomide 1Pharmacogenomic Variants 1Patient Comfort 1Paclitaxel 1PT-100 dipeptide 1Nutrition Assessment 1Mindfulness-Based Stress Reduction 1Mindfulness 1Magnetic Resonance Spectroscopy 1Health Promotion 1Everolimus 1Diet Therapy 1Carboplatin 1Biopsy 1Behavior Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Advanced Malignant Solid Neoplasm × dinaciclib × Clear all
NCT01434316 2026-04-13

Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors

National Cancer Institute (NCI)

Phase 1 Active not recruiting
121 enrolled
Other solid neoplasm

Advanced Malignant Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡